BCRX - BioCryst Pharmaceuticals, Inc.
RESEARCH TRIANGLE PARK, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Tuesday, September 15, 2026, at 9:15 a.m. ET.
Canada Pension Plan Investment Board bought a new position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 115,805 shares of the biotechnology company's stock, valued at approximately $1,158,000. A
Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
BioCryst Pharmaceuticals (BCRX) is evolving into a dual-product hereditary angioedema (HAE) franchise, targeting both oral and injectable prophylactic preferences. BCRX's ORLADEYO profit engine supports pipeline funding; Q2 2026 revenue reached $218.3M, with strong gross margins and positive cash flow independent of licensing receipts. The navenibart acquisition positions BCRX to capture injectable-preferring HAE patients, leveraging existing commercial infrastructure for operating leverage and customer retention.
The average of price targets set by Wall Street analysts indicates a potential upside of 108.2% in BioCryst (BCRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to pursue external deals. As large drugmakers prioritize multibillion dollar assets, small and midsize biotech companies are increasingly stepping in to develop and acquire rare disease drugs.
ADAR1 Capital Management LLC bought a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 133,000 shares of the biotechnology company's stock, valued at approximately $1,330,000. ADAR1 Capital Management LLC owned
— Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX - Get Free Report) have received a consensus rating of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 1
Bank of America Corp DE boosted its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 231.6% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 5,091,765 shares of the biotechnology company's stock after buying an additional 3,556,208 shares during the period. Bank
Assenagon Asset Management S.A. boosted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 51.6% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 353,044 shares of the biotechnology company's stock after purchasing an additional 120,097 shares during the period.
The consensus price target hints at a 98.7% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Investors need to pay close attention to BCRX stock based on the movements in the options market lately.
BioCryst Pharmaceuticals (NASDAQ:BCRX) closed at $9.84 on August 10, 2026, giving the Durham-based rare-disease specialist a market cap of roughly $2.5 billion.
BioCryst Pharmaceuticals, Inc. (BCRX) Q2 2026 Earnings Call Transcript
BioCryst Pharmaceuticals NASDAQ: BCRX reported second-quarter results marked by growth in ORLADEYO revenue, the start of shipments for its pediatric oral-pellet formulation, and completion of enrollment in its pivotal navenibart trial for hereditary angioedema, or HAE.
BioCryst Pharmaceuticals (BCRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.15 per share a year ago.
— Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 million — — Maintained Full Year 2026 ORLADEYO revenue guidance of $625 to $645 million and increased total revenue guidance to $690 million to $715 million — — Began shipping ORLADEYO oral pellets to pediatric patients on August 3 — — Completed enrollment in ALPHA-ORBIT, the ongoing pivotal study of navenibart — RESEARCH TRIANGLE PARK, N.C., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported financial results for the quarter ended June 30, 2026, and provided a business update.
ADAR1 Capital Management LLC boosted its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 133.3% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 105,000 shares of the biotechnology company's stock after acquiring an additional 60,000 shares during the
RESEARCH TRIANGLE PARK, N.C., July 22, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2026 financial results on Wednesday, August 5, 2026.